The androgen-signaling pathway is important for the growth and progression of prostate cancer cells. The growth-promoting effects of androgen on prostate cells are mediated mostly through the androgen receptor (AR). There is increasing evidence that transcription activation by AR is mediated through interaction with other co-factors. β-catenin plays a critical role in embryonic development and tumorigenesis through its effects on E-cadherin-mediated cell adhesion and Wnt-dependent signal transduction. Here, we demonstrate that a specific protein-protein interaction occurs between β−catenin and AR. Unlike the steroid hormone receptor coactivator 1 (SRC1), β−catenin showed a strong interaction with AR but not with other steroid hormone receptors such as PRβ, ERα, and GR. The ligand binding domain of AR and the N-terminus combined with the first 6 armadillo repeats of β−catenin were shown to be necessary for the interaction. Through this specific interaction, β−catenin augments the ligand-dependent activity of AR in prostate cancer cells. Moreover, expression of E-cadherin in E-cadherin negative prostate cancer cells results in redistribution of the cytoplasmic β-catenin to the cell membrane and reduction of AR-mediated transcription. These data suggest that loss of E-cadherin can elevate the cellular levels of β-catenin in prostate cancer cells, which may directly contribute to invasiveness and a more malignant tumor phenotype by augmenting AR activity during prostate cancer progression. 
INTRODUCTION
conjugated to Alexa-488 (20 µg/ml; Molecular Probes, Eugene, OR). β-catenin was stained with a mouse monoclonal anti-β-catenin antibody conjugated to TRITC (10 µg/ml; Transduction Laboratories).
RESULTS

Androgen receptor interacts with catenin in a ligand-dependent manner.
Using a bait construct containing the LBD and hinge region of the AR, we employed a modified yeast two-hybrid system to identify proteins that interact with AR in an androgendependent manner (17, 18) . Of 2x10 7 transformants, 73 grew under selective conditions and showed increased adenine and β-gal production in medium containing 100 nM dihydrotestosterone (DHT). Rescue of the plasmids and sequencing of the inserts revealed several different cDNAs, including the previously identified SRC1 (22) , an AR associated protein (ARA70) (19) , and several other AR interacting proteins identified recently by others or us (17, 21, 23) . Importantly, 23 of these clones perfectly matched the sequence of the full-length coding region of β-catenin. To confirm the interaction, we co-transformed one of these β-catenin clones with various constructs containing either GAL4DBD alone, or the AR fusion proteins with a partial transactivation domain (pTAD), the DBD, and the LBD (Fig. 1A) . pGAD10-β-catenin showed a specific interaction with GAL4DBD-AR-LBD by producing adenine in the presence of 100 nM DHT (data not shown). In the liquid β-gal assays, pGAD10-β-catenin showed an approximately 97-fold induction with 2B, deletion of the C-terminal activation domain of β−catenin (β−cat-t671) alone, or in combination with the last five armadillo repeats (β−cat-t423) did not significantly affect the binding. However, a mutant in which the N-terminal activation domain alone (β−cat-t134-671), or in combination with the central armadillo domain (β−cat-t671-781) was deleted showed no interaction. This result suggests that the primary binding region for AR spans the N-terminus and the first seven armadillo repeats of β−catenin.
To precisely map the interacting region, a series of truncated mutants were made in which each single armadillo repeat was subsequently deleted (Fig. 3A) . The deletion constructs containing the N-terminal region and the first six repeats (β−cat-t393) showed about two-thirds the activity of the full-length protein (β−cat-F) (Fig. 3A) . However by deleting repeat 6 (β-cat-t350), the interaction was essentially abolished, indicating that armadillo repeat 6 is crucial for binding to AR.
Deletion of repeats 1-5 obviously had little further effect.
It has been shown that most β-catenin binding proteins such as Tcf/LEF family members (24) , axin (25) , APC (26, 27) , and cadherins (26, 28) bind β-catenin mainly through the central armadillo repeats. In most of cases, the first 10 repeats is required for the interactions and a minimum of 6-7 repeats are sufficient for detectable binding (29, 30) . Those data are consistent with our finding that deletion of repeat 6 fully abolished the interaction with AR. To more precisely map the interaction region within the first six armadillo repeats, we used a PCR based, site directed mutagenesis techniques to generate several internal deletion mutants. As shown in the figure, the wild type β-catenin and the mutant with deletion of repeat 7 (∆R7) or 12 (∆R12) all reacted avidly with the AR-LBD. In contrast, mutants lacking repeat 6 (∆R6) showed no interaction with the AR-LBD (Fig. 3B) . Moreover, deletion of repeat 5 alone also fully abolished the interaction, indicating that the armadillo repeats 1-5 may be also involved in the interaction. To confirm this result, an additional internal deletion mutant lacking repeat 3 (∆R3) was generated and tested. As we expected, the mutant also showed no interaction with AR (data not shown). Taken together, the results allow us to conclude that the region spanning armadillo repeats 1-6 is mainly responsible for binding to AR.
catenin interacts with AR in vitro & in vivo.
Physical interaction between AR and β-catenin was further assessed by GST pull-down experiments. A series of GST fusion proteins with the full length β-catenin and internal deletion mutants were generated and immobilized onto a glutathione-Sepharose matrix. The binding of 35 Smethionine labeled AR protein to GST-β-catenin fusion proteins was analyzed by SDS-PAGE and detected by autoradiography. As shown in Figure 4A , AR protein bound to the GST fusion protein containing wild type β-catenin and its mutants lacking either repeat 7 or 12. The interaction is more pronounced in the presence of DHT than in the absence of DHT, and as much as 5% of the input protein was recovered (Fig. 4A ). However, a significant reduction of binding was observed between the AR protein and the β-catenin mutants lacking repeat 6 when equal amounts of the GST fusion proteins were used in the experiments (Fig. 4B) . These results are consistent with our observations from the yeast-two hybrid system and show a domain-dependent interaction in vitro.
To confirm that endogenous AR and β-catenin are physically associated in intact cells, coimmunoprecipitation assays were carried out to detect a possible protein complex in a prostate cancer cell line, LNCaP. Using specific antibodies, we further confirmed that AR and β-catenin proteins form a protein complex in LNCaP cells and the formation of AR and β-catenin complexes in these cells was also enhanced by DHT (data not shown). These results are consistent with a recent report by Truica and colleagues (31) .
Next, we examined whether a dynamic interaction between β−catenin and AR existed in cells. Flag-tagged vectors containing either full-length or truncated mutants of β−catenin were transfected into CV-1 cells and the expressed protein showed a cytoplasmic and nuclear distribution, which was not altered by treatment with DHT (data not shown). Overexpression of β-catenin plasmids with AR vector, in the absence of DHT, showed the same cellular distribution as transfection of β-catenin plasmid alone, while transfected AR protein is localized mainly in the cytoplasm (Fig. 4D, panels 1, 3, and 5 ). In the presence of DHT, AR proteins are fully translocated into the nuclei (panels 2, 4, and 6). Importantly, both the wild-type (panel 2) and the ∆R12 mutant of β−catenin (panel 6) showed increased levels of nuclear translocation when cotransfected with AR compared to cells transfected with the ∆R6 mutant of β−catenin in which cytoplasmic staining of β-catenin persisted (panel 4). These results provide the first evidence that β−catenin can translocate into the nucleus as part of a complex with AR by an interaction through armadillo repeat 6.
-catenin binds selectively to the AR.
To assess the possibility that β-catenin functions as a general co-activator of nuclear receptors, we examined the interaction of β-catenin with other members of the nuclear receptor family in yeast. The LBD of ERα, PRβ, and VDR were generated and fused to GAL-DBD in the pGBT9 vector. These plasmids were co-transformed with either pGAD10-β-catenin or pGAD10-SRC1 as a positive control in the presence of corresponding ligands. The yeast transformants were grown on the selective media and a liquid β-gal assay was performed to quantify the interactions.
All receptors were shown to have a ligand-dependent interaction with the SRC1 (Fig. 5A) , which is consistent with the previous reports (22, 32) . However, β-catenin showed a strong interaction with AR but not with ERα and PRβ. VDR showed a weaker interaction with β-catenin in comparison to SRC1. These results indicate that β-catenin, SRC1, only selectively interacts with AR.
The specificity of interaction between β-catenin and AR proteins was further tested in CV1 cells. Since AR, GR, and PRβ all can activate the MMTV promoter, we examined whether β-catenin is able to enhance GR and PRβ activity under identical experimental condition. Transfection experiments were repeated with β-catenin and AR, GR, and PRβ expression plasmids, along with a luciferase reporter plasmid regulated by an MMTV promoter containing the steroid hormone responsive elements (HREs) (33,34). As shown in Fig. 5B , all receptors showed a liganddependent transactivation with the MMTV promoter. However, β-catenin specifically augmented only AR-mediated transcription but not GR and PRβ (Fig. 5B) . Taken together, our results suggest that β-catenin differs from SRC1, and selectively affects AR.
-catenin augments AR-mediated transcription through specific protein-protein interaction.
Transient transfection assays were performed to further investigate the possible effect of β-catenin on AR mediated transcription. Plasmids capable of expressing AR, wild type or mutants of β-catenin, and a luciferase reporter plasmid regulated by the MMTV-LTR (MMTVpA3-Luc) were transfected into CV-1 cells (35). A nearly 3 fold ligand-dependent transactivation was observed in the cells transfected with AR plasmid alone. Co-transfection of the wild type of β-catenin expression construct increased AR activity to nearly 10-fold above baseline (Fig. 6A) . Expression of the β-catenin mutant lacking the armadillo repeat 12 still showed 6 to 7-fold induction, whereas the mutants lacking repeat 6 showed no enhancement on AR-mediated transcription (Fig. 6A ). The data indicates that β-catenin augments AR-mediated transcription and this enhancement is mediated through the physical interaction between these proteins. β-catenin can form a transcriptional complex with members of the Tcf/LEF family to activate target genes (7, 25) . To ensure that augmentation of the MMTV promoter by β-catenin is mediated solely through the AR, rather than through other transcription factors, we examined the effect of β-catenin on the transcription from a luciferase reporter driven by a minimum promoter with two androgen response elements (AREs). A similar ligand-dependent enhancement of AR-mediated transcription was observed with the full-length β-catenin construct (Fig. 6B ). As we observed above, the mutant lacking repeat 6 showed no enhancement. Interestingly, ARA70, an AR coactivator, did not affect the AR-mediated transcription of this minimum promoter. Nevertheless, these results further confirm that β-catenin is truly a co-activator of AR and can enhance ARmediated transcription on a minimum promoter with AREs.
To evaluate the enhancement by β-catenin of AR-mediated transcription in a physiologically relevant cellular context, an AR positive prostate cancer cell line, LNCaP, were transfected with β-catenin expression constructs and a luciferase reporter driven by the 7 Kb prostate specific antigen (PSA) gene promoter, which is an AR-regulated target gene and has been widely used as a prostatespecific tumor marker (36). As seen in Fig. 6C , the wild type and repeat 12 deletion mutants of β-catenin enhance endogenous AR-mediated transcription from the PSA promoter, and the wild type β-catenin showed a dose-dependent effect. However, as we observed previously, the mutant with a deletion of repeat 6 showed no effect. These data further support the transfection data with MMTV and ARE-minimum promoters, and demonstrate that the augmentation of endogenous AR activity by β-catenin in prostate cancer cells is mediated through the AR/β-catenin interaction.
E-cadherin modulates the level of cytoplasmic pools of -catenin to enhance ARmediated transcription.
The observation that β-catenin can function as an oncogene when inappropriately expressed highlights the importance of regulating β-catenin level in the cells. Recent studies show that tumor cells can bypass this regulation by acquiring loss-of-function mutations in components of the destruction complex or by altering regulatory sequences in β-catenin itself, which makes it impervious to the effects of the destruction complex. Moreover. in normal epithelial tissues, Ecadherin complexes with the actin cytoskeleton via catenins to maintain the functional characteristics of epithelia (37,38). Disruption of this complex, due primarily to loss or decreased expression Ecadherin, is frequently observed in many advanced, poorly differentiated prostate cancer patient samples (39, 40) . It has been reported that β-catenin is mainly accumulated in both the cytoplasm and the nucleus of some prostate cancer cell lines in which there is a reduction or loss of E-cadherin expression (41, 42) . To test whether loss of E-cadherin can augment AR activity by increasing cytoplasmic and nuclear levels of β−catenin, we stably transfected E-cadherin expression vectors into an E-cadherin negative prostate cancer cell line, TSU.pr-1. In TSU.pr-1 cells, E-cadherin expression is silenced by hypermethylation of the promoter region (41) . Immunostaining of the polycolonal subline transfected with the E-cadherin expression vector (TSU.pr-1/E-CAD) showed that β-catenin is partially redistributed into the cell membrane, resulting in reduction of its cytoplasmic and nuclear levels compared the pool transfected with a control vector, TSU.pr-1/Neo (Fig. 7A) . Transfection of an AR expression vector and the PSA-luciferase reporter into these two TSU.pr-1 sublines showed a ligand dependent AR activity (Fig. 7B ). However, a stronger AR activity was observed in TSU.pr-1/Neo cells than TSU.pr-1/E-CAD cells with equal amounts of AR plasmid and a dosedependent induction was only shown in TSU.pr-1/Neo cells. Using an ARE-luciferase reporter, we also showed a similar dose-dependent augmentation of AR activity by the cytoplasmic pool of endogenous β−catenin in TSU.pr-1/Neo cells (Fig. 7E) . The results from the above experiments suggest that endogenous β−catenin in the cytoplasmic pool can augment AR-mediated transcription and that reducing its level can decrease this enhancement.
To further confirm that the enhancement of AR activity in TSU.pr-1/Neo cells was directly mediated by β−catenin, we repeated the above experiments with an antisense construct of β− catenin. As shown in Figure 7C , enhancement of ligand dependent AR activation in TSU.pr-1/Neo cells was specifically repressed by co-transfection with the β−catenin antisense construct. This was correlated with a decreased level of β−catenin protein in the cells (Fig. 7D) . To ensure that the enhancement of AR activity in TSU.pr-1/Neo cells was specifically mediated by endogenous β− catenin, rather than a general effect on the basal transcriptional machinery or other nonspecific effects from this subline, we examined the transcriptional activities of other nuclear hormone receptors in the cells. As shown in Figure 7F , unlike the results that we observed in Figure 7E Using immunofluorescence studies, we first demonstrated that β−catenin can translocate into the nucleus as part of a complex with AR. These multiple lines of evidence clearly indicated that AR and β-catenin proteins can specifically interact and given the consequences of the interaction, probably represents a biologically relevant interaction.
In this study, we also demonstrated a functional interaction between AR and β-catenin in prostate cancer cells, which is consistent with a recent report by Truica et al (31) . Importantly, using internal deletion mutants of β-catenin, we showed that enhancement of intact, natural AR- A number of cofactors have been identified that interact with the LBD of nuclear hormone receptors (22, (46) (47) (48) . Among them, the best characterized coactivators are the p160 family and p300/CBP, which appear to bind to most of the nuclear receptors in a ligand-dependent manner through the conserved protein motif, LXXLL (49, 50) . The motif forms a two-turn amphipathic alpha-helix which binds to a hydrophobic cleft in the AF2 domain of nuclear receptors. β-catenin contains five LXXLL motifs all of which are located in a central armadillo domain (29) . Among them, four are localized in the second helix of the armadillo repeats 1, 7, 10, and 12. Based on the structure of β−catenin protein, the Leu residues in these motifs are buried in the hydrophobic core of the armadillo repeats and it seems unlikely that they would interact with AR or other nuclear hormone receptors (29) . Using a series of deletion mutants, we have shown that constructs lacking the repeats 7, 10, and 12 retained the capacity to bind AR, whereas the construct lacking only repeat 6 fully abolished the interaction. Under identical experimental conditions, other steroid hormone receptors such as ERα, PRβ, and GR did not show an interaction with β-catenin. These data are consistent with earlier structural study of β-catenin and suggest that the LXXLL motifs in β-catenin may not directly contribute to the interaction that we have identified between AR and β-catenin. An earlier report showed that β-catenin associates with a retinoic acid receptor (RAR) and enhance activation of a retinoic acid responsive promoter (51) . In the yeast two-hybrid system, we also observed a weak interaction between β-catenin and VDR. In this regard, it will be important to determine the protein motifs involved in the interaction with these receptors, which will expand our understanding of the cross-talk between β-catenin and nuclear hormone receptors.
The cellular levels of β-catenin are tightly regulated in normal cells. Mutations affecting the degradation of β-catenin can increase the cellular levels of the proteins to induce neoplastic transformation (52) . A tumor suppressor, APC, which is an important component of the degradation machinery, was frequently mutated in both sporadic and hereditary colorectal tumors (12) . Mutations of β-catenin within the GSK binding region were also found in prostate cancer samples (53) , suggesting a potential role of β-catenin in prostate cancer cells. Our results showing a detailed molecular basis of the interaction of β-catenin with AR provide a direct link between β-catenin and androgen signaling. Due to an abnormal cadherin-catenin interaction in the cell membrane, increasing the cytoplasmic and nuclear levels of β-catenin as a consequence of loss of E-cadherin is frequently observed in late stages of prostate cancer cells (15) . Using an E-cadherin negative prostate cancer cell line, TSU.pr-1, we further showed that the endogenous β-catenin that accumulated in cytoplasm and nucleus are capable of augmenting AR-mediated transcription, and the effect of β-catenin on AR can be enhanced by loss of E-cadherin expression. These results suggest that loss of E-cadherin expression may promote AR-mediated cell growth in late stages of prostate cancer. In addition, as observed previously (16), β-catenin was shown to have no effect with a TCF reporter gene in TSU.pr-1 cells (data not shown). A similar observation was also reported recently in breast cancer cells containing transcriptional silencing of the E-cadherin gene (54) . This raises the question as to whether the growth-promoting effect of β−catenin is mediated through other partners rather than through the TCF/LEF pathway in prostate cancer or/and other tumor cells.
Our results suggest a new role for E-cadherin and β−catenin in prostate cancer cells. During prostate cancer progression, loss of expression of E-cadherin frequently occurs, which leads to an increase in the cytoplasmic levels of β−catenin. Under normal conditions, the cellular β−catenin is tightly regulated by the destruction complex which includes APC, GSK3β, and axin. When the functional activities of these components are changed, such as by mutation or aberrant expression of the proteins, the excessive free β−catenins overload the system and are translocated into the nucleus, where they specifically interact with the AR to augment AR-mediated transcription. In addition, enhancement by β−catenin may also be able to maintain or increase AR activity in the setting of decreased androgen levels during androgen ablation therapy, which can adapt prostate cancer cells to become androgen insensitive. Therefore, studying the interaction of β−catenin with AR in prostate cancer should provide fresh insight into the progression of prostate cancer that may help us to identify new steps that can be targeted for prostate cancer treatment. 
